cyclic-gmp and Rectal-Neoplasms

Levels of urine excretion of cAMP and cGMP and their ratio were studied in patients with colorectal cancer in the course of a 3-year follow-up. At 12-36 months after surgery, the cAMP/cGMP ratio was higher (mainly due to decreased cGMP level) in disease-free patients than in those with recurrence or metastases. Preoperative level of cyclic nucleotide excretion cannot serve as prognostic factor for recurrence or metastasis development whereas levels of cAMP and cGMP measured within a follow-up period may be used for monitoring the course of colorectal cancer. The cAMP/cGMP ratio tended to rise in application of drugs controlling hyperlipidemia and other signs of cancrophilia.

Topics: Adult; Colonic Neoplasms; Cyclic AMP; Cyclic GMP; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Rectal Neoplasms; Time Factors

Tissues from tumor and normal intestine were examined in 44 patients suffering from colonic and rectal cancer. The study established elevated levels of cholesterol (chiefly, cholesterol esters) and phospholipids, as compared with normal tissue. Two groups were identified among the cancer patients on the basis of the ratio of K = (Formula: see text). Cases with a relatively low value of K revealed higher levels of body fat and hyperlipidemia. That was matched by relatively higher concentrations of cholesterol and its esters, but not phospholipids, in tumor tissue, as compared with normal one. The relationship between cyclic nucleotide metabolism disorders in neoplastic tissue and lipid metabolism in cancer patients is discussed.

Topics: Adenocarcinoma; Cholesterol; Cholesterol Esters; Colonic Neoplasms; Cyclic AMP; Cyclic GMP; Humans; Middle Aged; Phospholipids; Rectal Neoplasms

Cyclic nucleotide phosphodiesterase activity has been measured in muscle biopsies taken from healthy controls and from cancer patients. In both groups the muscles were clinically and morphologically normal. The phosphodiesterase activity was significantly increased in muscles from cancer patients using both cyclic AMP and cyclic GMP as substrate. These findings are in line with previous reports indicating that malignancy may interfere with metabolism of the host muscular tissues, and suggest the possibility that the observed biochemical changes might be an aspect of an early muscle neurogenic involvement.

Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Carcinoma; Cyclic AMP; Cyclic GMP; Humans; Liver Neoplasms; Lung Neoplasms; Muscles; Phosphoric Diester Hydrolases; Rectal Neoplasms; Stomach Neoplasms